Our data show that the proteasome inhibitor bortezomib, a widely-used drug in MM, has no effect on AIF1 expression, cleavage and localization; suggesting that PAA could be applied in MM patients, who are resistant to bortezomib. This evidence concerns the gene AIF1 and Miyoshi myopathy.